A single dose of the orexin-1 (
OX1) receptor antagonist 1-(2-methylbenzoxazol-6-yl)-3-[1,5] naphthyridin-4-yl
urea hydrochloride (SB-334867-A) reduces
orexin-A-induced feeding and natural feeding in Sprague Dawley rats. In this study, the anti-
obesity effects of
SB-334867-A were determined in genetically obese (ob/ob) mice dosed with
SB-334867-A (30 mg/kg, i.p.) once daily for 7 days, and then twice daily for a further 7 days.
SB-334867-A reduced cumulative food intake and
body weight gain over 14 days. Total fat mass gain, determined by Dual Emission X-ray Absorptiometry, was reduced, while gain in fat-free mass was unchanged. Fasting (5 h)
blood glucose was also reduced at the end of the study, with a trend to reduced plasma
insulin. Interscapular brown adipose tissue (BAT) weight was reduced, the tissue was noticeably darker in colour and quantitative PCR (TaqMan) analysis of this tissue showed a trend to an increase in uncoupling protein-1
mRNA expression, suggesting that
SB-334867-A might stimulate thermogenesis. This was confirmed in a separate study in which a single dose of
SB-334867-A (30 mg/kg, i.p.) increased metabolic rate over 4 h in ob/ob mice.
OX1 receptor mRNA was detected in BAT, and its expression was increased by 58% by treatment with
SB-334867-A. This is the first demonstration that
OX1 receptor antagonists have potential as both anti-
obesity and anti-diabetic agents.